NCT06849986View on ClinicalTrials.gov

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Soft Tissue SarcomasAngiosarcomaFibrosarcomaLeiomyosarcomaPleomorphic LiposarcomaMalignant Peripheral Nerve Sheath Tumor (MPNST)Desmoplastic Small Round Cell Tumor
Interventions
DRUG

Tislelizumab+liposomal doxorubicin+ifosfamide

Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 Ifosfamide (IFO) 3 g/m2/day on days 1 to 3 Tislelizumab 200mg on day 1, administered by intravenous infusion, every 3 weeks

Trial Locations (1)

200030

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER